Efficacy and safety of catheter ablation for Brugada syndrome: an updated systematic review
-
Published:2022-04-22
Issue:
Volume:
Page:
-
ISSN:1861-0684
-
Container-title:Clinical Research in Cardiology
-
language:en
-
Short-container-title:Clin Res Cardiol
Author:
Kotake Yasuhito, Barua Sumita, Kazi Samia, Virk Sohaib, Bhaskaran Ashwin, Campbell Timothy, Bennett Richard G., Kumar SaurabhORCID
Abstract
Abstract
Background
Patients with Brugada syndrome (BrS) may experience recurrent ventricular arrhythmias (VAs). Catheter ablation is becoming an emerging paradigm for treatment of BrS.
Objective
To assess the efficacy and safety of catheter ablation in BrS in an updated systematic review.
Methods
We comprehensively searched the databases of Pubmed/Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception to 11th of August 2021.
Results
Fifty-six studies involving 388 patients were included. A substrate-based strategy was used in 338 cases (87%), and a strategy of targeting premature ventricular complex (PVCs)/ventricular tachycardias (VTs) that triggered ventricular fibrillation (VF) in 47 cases (12%), with combined abnormal electrogram and PVC/VT ablation in 3 cases (1%). Sodium channel blocker was frequently used to augment the arrhythmogenic substrate in 309/388 cases (80%), which included a variety of agents, of which ajmaline was most commonly used. After ablation procedure, the pooled incidence of non-inducibility of VA was 87.1% (95% confidence interval [CI], 73.4–94.3; I2 = 51%), and acute resolution of type I ECG was seen in 74.5% (95% CI [52.3–88.6]; I2 = 75%). Over a weighted mean follow up of 28 months, 7.6% (95% CI [2.1–24]; I2 = 67%) had recurrence of type I ECG either spontaneously or with drug challenge and 17.6% (95% CI [10.2–28.6]; I2 = 60%) had recurrence of VA.
Conclusion
Catheter ablation appears to be an efficacious strategy for elimination of arrhythmias or substrate associated with BrS. Further study is needed to identify which patients stand to benefit, and optimal provocation protocol for identifying ablation targets.
Graphical abstract
Funder
NSW Health University of Sydney
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Reference63 articles.
1. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C (2013) HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10(12):1932–1963. https://doi.org/10.1016/j.hrthm.2013.05.014 2. Conte G, Sieira J, Ciconte G, de Asmundis C, Chierchia GB, Baltogiannis G, Di Giovanni G, La Meir M, Wellens F, Czapla J, Wauters K, Levinstein M, Saitoh Y, Irfan G, Julia J, Pappaert G, Brugada P (2015) Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol 65(9):879–888. https://doi.org/10.1016/j.jacc.2014.12.031 3. Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich A, Jirasirirojanakorn K, Likittanasombat K, Bhuripanyo K, Ngarmukos T (2011) Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 123(12):1270–1279. https://doi.org/10.1161/CIRCULATIONAHA.110.972612 4. Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, Makita N, Kowase S, Boonmee N, Vitayakritsirikul V, Ratanarapee S, Sharma S, van der Wal AC, Christiansen M, Tan HL, Wilde AA, Nogami A, Sheppard MN, Veerakul G, Behr ER (2015) Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome. J Am Coll Cardiol 66(18):1976–1986. https://doi.org/10.1016/j.jacc.2015.08.862 5. Brugada J, Pappone C, Berruezo A, Vicedomini G, Manguso F, Ciconte G, Giannelli L, Santinelli V (2015) Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol 8(6):1373–1381. https://doi.org/10.1161/CIRCEP.115.003220
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|